insights_auto
Why is HROW down 3.64%?
Dive Deeperchevron_right
HROW:NASDAQ
Harrow Inc
$28.30
arrow_downward
-3.64%(-1.07) 1D
$28.35
arrow_upward
+0.18% (+0.050)todayPre-market
Closed: Nov 12, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HROW...
Open
$29.54
High
$29.54
Low
$28.16
Mkt. cap
1.06B
Avg. vol.
694.18K
Volume
17.00
52-wk high
$54.85
52-wk low
$25.76
EPS
-$0.77
Beta
0.18
Shares outstanding
37.53M
No. of employees
373
Open
$29.54
High
$29.54
Low
$28.16
Mkt. cap
1.06B
Avg. vol.
694.18K
Volume
17.00
52-wk high
$54.85
52-wk low
$25.76
EPS
-$0.77
Beta
0.18
Shares outstanding
37.53M
No. of employees
373
News stories
From web sources and news partners
VisionMonday.com
·
2 days ago
Harrow Reports Record Third Quarter 2026 Revenue Driven by Branded Products
Yahoo Finance
·
3 days ago
Harrow: Q3 Earnings Snapshot
Profile
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary. Wikipedia
About Harrow Inc
CEOMark L. Baum Esq.
Employees373
Founded2012
HeadquartersNashville, Tennessee, United States
SectorHealth Care
IndustryPharmaceutical industry
Websiteharrow.com